CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
|Articles|January 7, 2013
Health Insurers Raise Some Rates by Double Digits
Advertisement
Health insurance companies across the country are seeking and winning double-digit increases in premiums for some customers, even though one of the biggest objectives of the Obama administration’s health care law was to stem the rapid rise in insurance costs for consumers.
Particularly vulnerable to the high rates are small businesses and people who do not have employer-provided insurance and must buy it on their own.
Read the full story:
Source: The New York Times
Advertisement
Related to this article
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
4
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
5